Article

Effects of BRCA1 and BRCA2 mutations on female fertility

Department of Family and Consumer Studies, University of Utah, 225 South 1400 East Alfred Emery Building 228, Salt Lake City, UT 84112, USA.
Proceedings of the Royal Society B: Biological Sciences (Impact Factor: 5.29). 04/2012; 279(1732):1389-95. DOI: 10.1098/rspb.2011.1697
Source: PubMed

ABSTRACT Women with BRCA1/2 mutations have a significantly higher lifetime risk of developing breast or ovarian cancer. We suggest that female mutation carriers may have improved fitness owing to enhanced fertility relative to non-carriers. Here we show that women who are carriers of BRCA1/2 mutations living in natural fertility conditions have excess fertility as well as excess post-reproductive mortality in relation to controls. Individuals who tested positive for BRCA1/2 mutations who linked into multi-generational pedigrees within the Utah Population Database were used to identify putative obligate carriers. We find that women born before 1930 who are mutation carriers have significantly more children than controls and have excess post-reproductive mortality risks. They also have shorter birth intervals and end child-bearing later than controls. For contemporary women tested directly for BRCA1/2 mutations, an era when modern contraceptives are available, differences in fertility and mortality persist but are attenuated. Our findings suggest the need to re-examine the wider role played by BRCA1/2 mutations. Elevated fertility of female mutation carriers indicates that they are more fecund despite their elevated post-reproductive mortality risks.

Download full-text

Full-text

Available from: Ken R Smith, Aug 25, 2015
0 Followers
 · 
113 Views
  • Source
    • "In the context of cancer, this phenomenon antagonistic pleiotropy -has been found in animal models, perhaps the most stunning case being Xiphophorus fish, where late life melanoma-promoting oncogene alleles are associated with early life advantages (Fernandez and Bowser 2010). There is increasing evidence that some human cancers occurring at later ages may result from negative trade-offs with early age adaptations (Summers and Crespi 2008, 2010; Smith et al. 2012), such as, for instance, high birth weight – a life-history trait that has a genetic basis and is also associated with fitness benefits early in life (e.g., survival until maturity, Thomas et al. 2012b; Smith et al. 2012). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Since the mid 1970s, cancer has been described as a process of Darwinian evolution, with somatic cellular selection and evolution being the fundamental processes leading to malignancy and its many manifestations (neoangiogenesis, evasion of the immune system, metastasis, and resistance to therapies). Historically, little attention has been placed on applications of evolutionary biology to understanding and controlling neoplastic progression and to prevent therapeutic failures. This is now beginning to change, and there is a growing international interest in the interface between cancer and evolutionary biology. The objective of this introduction is first to describe the basic ideas and concepts linking evolutionary biology to cancer. We then present four major fronts where the evolutionary perspective is most developed, namely laboratory and clinical models, mathematical models, databases, and techniques and assays. Finally, we discuss several of the most promising challenges and future prospects in this interdisciplinary research direction in the war against cancer.
    Evolutionary Applications 01/2013; 6(1):1-10. DOI:10.1111/eva.12021 · 4.57 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: OPINION STATEMENT: The increased availability of assisted reproductive technologies (ART) allows women with fertility issues to increase their chances of a successful pregnancy with the use of medications that, in some cases, increase circulating estrogens. There has been significant concern that the use of these medications will increase the risk of hormone-sensitive cancers such as breast, ovarian and uterine malignancies. Additionally, for those women who are diagnosed with a breast cancer during their reproductive years, this diagnosis can be particularly difficult as future fertility is a major concern for many young breast cancer survivors. With the current available data, there does not appear to be a statistically significant increase in the risk of developing breast cancer with ART, although several series suggest a potential possible related increase in borderline ovarian and uterine cancers. For breast cancer survivors, there does not appear to be an increased risk of death associated with subsequent pregnancies when compared with breast cancer patients who did not have subsequent pregnancies, although waiting at least 2 years after the diagnosis of breast cancer potentially may convey a protective effect. Therefore, when systemic therapy for breast cancer is recommended, early counseling and referral to a reproductive endocrinologist is warranted to provide optimal fertility preservation options. Further safety and outcomes studies are warranted for children.
    Current Treatment Options in Oncology 03/2012; 13(2):137-45. DOI:10.1007/s11864-012-0185-5 · 3.24 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Evolution has long provided a foundation for population genetics, but some major advances in evolutionary biology from the twentieth century that provide foundations for evolutionary medicine are only now being applied in molecular medicine. They include the need for both proximate and evolutionary explanations, kin selection, evolutionary models for cooperation, competition between alleles, co-evolution, and new strategies for tracing phylogenies and identifying signals of selection. Recent advances in genomics are transforming evolutionary biology in ways that create even more opportunities for progress at its interfaces with genetics, medicine, and public health. This article reviews 15 evolutionary principles and their applications in molecular medicine in hopes that readers will use them and related principles to speed the development of evolutionary molecular medicine.
    Journal of Molecular Medicine 04/2012; 90(5):509-22. DOI:10.1007/s00109-012-0889-9 · 4.74 Impact Factor
Show more